FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807009310> ?p ?o ?g. }

• W2807009310 abstract "While data from several studies over the last decade has demonstrated that introduction of immunologic checkpoint blockage therapy with anti-CTLA-4/PD-1 drugs leads to improved survival in metastatic melanoma patients, relatively little is known about brain-specific therapeutic response and adverse events in the context of immunotherapeutic treatment of intracranial disease. Here we report two independent cases of new intracranial metastases presenting after initiation of combined checkpoint blockade Ipilimumab and Nivolumab for recurrent metastatic melanoma in the context of positive systemic disease response.Case #1: A 43-year-old Caucasian male with Stage III melanoma of the left knee had subsequent nodal, hepatic and osseous metastases and was started on ipilimumab/nivolumab. He developed an intractable headache one week later. MRI revealed new enhancing and hemorrhagic brain metastases. After 6 weeks of immunotherapy, there was interval hemorrhage of a dominant intracranial lesion but substantial improvement in systemic metastatic disease. Durable, near complete intracranial and systemic response was achieved after completion of both induction and maintenance immunotherapy. Case #2: A 58-year old Caucasian woman with stage II melanoma of the right index finger developed cutaneous, pulmonary and hepatic metastases within 4 months of adjuvant radiation. Although combined checkpoint blockade resulted in improvement in both cutaneous and systemic disease, brain MR performed for eye discomfort demonstrated new enhancing and hemorrhagic brain metastases. Serial MR imaging five months later revealed only a solitary focus of brain enhancement with continued improved systemic disease.These cases raise the question of whether the initial immune activation and modulation of the blood brain barrier by Ipilimumab/Nivolumab somehow unmasks previously clinically silent metastatic disease, rather than representing new or progressive metastatic disease. An overview of currently available literature discussing the role of immune checkpoint blockade in the treatment of intracranial metastatic melanoma will be provided, as well as discussion highlighting the need for future work elucidating the response of brain metastases to anti-CTLA/PD-1 drugs and documentation of brain-specific adverse events." @default.
• W2807009310 created "2018-06-13" @default.
• W2807009310 creator A5029783882 @default.
• W2807009310 creator A5032523423 @default.
• W2807009310 creator A5039814300 @default.
• W2807009310 creator A5046692770 @default.
• W2807009310 date "2018-05-09" @default.
• W2807009310 modified "2023-09-27" @default.
• W2807009310 title "Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review" @default.
• W2807009310 cites W1968221752 @default.
• W2807009310 cites W1969062072 @default.
• W2807009310 cites W2048644854 @default.
• W2807009310 cites W2067893090 @default.
• W2807009310 cites W2097995306 @default.
• W2807009310 cites W2098405842 @default.
• W2807009310 cites W2103220202 @default.
• W2807009310 cites W2111404068 @default.
• W2807009310 cites W2133857293 @default.
• W2807009310 cites W2137723371 @default.
• W2807009310 cites W2160379492 @default.
• W2807009310 cites W2160766792 @default.
• W2807009310 cites W2225066468 @default.
• W2807009310 cites W2295218932 @default.
• W2807009310 cites W2336162936 @default.
• W2807009310 cites W2347059916 @default.
• W2807009310 cites W2482589824 @default.
• W2807009310 cites W2890815045 @default.
• W2807009310 doi "https://doi.org/10.1186/s12885-018-4470-y" @default.
• W2807009310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5943996" @default.
• W2807009310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29743050" @default.
• W2807009310 hasPublicationYear "2018" @default.
• W2807009310 type Work @default.
• W2807009310 sameAs 2807009310 @default.
• W2807009310 citedByCount "8" @default.
• W2807009310 countsByYear W28070093102019 @default.
• W2807009310 countsByYear W28070093102020 @default.
• W2807009310 countsByYear W28070093102021 @default.
• W2807009310 countsByYear W28070093102022 @default.
• W2807009310 countsByYear W28070093102023 @default.
• W2807009310 crossrefType "journal-article" @default.
• W2807009310 hasAuthorship W2807009310A5029783882 @default.
• W2807009310 hasAuthorship W2807009310A5032523423 @default.
• W2807009310 hasAuthorship W2807009310A5039814300 @default.
• W2807009310 hasAuthorship W2807009310A5046692770 @default.
• W2807009310 hasBestOaLocation W28070093101 @default.
• W2807009310 hasConcept C121608353 @default.
• W2807009310 hasConcept C126322002 @default.
• W2807009310 hasConcept C141071460 @default.
• W2807009310 hasConcept C143998085 @default.
• W2807009310 hasConcept C151730666 @default.
• W2807009310 hasConcept C197934379 @default.
• W2807009310 hasConcept C2777658100 @default.
• W2807009310 hasConcept C2777701055 @default.
• W2807009310 hasConcept C2779343474 @default.
• W2807009310 hasConcept C2780030458 @default.
• W2807009310 hasConcept C2780140570 @default.
• W2807009310 hasConcept C2781433595 @default.
• W2807009310 hasConcept C502942594 @default.
• W2807009310 hasConcept C71924100 @default.
• W2807009310 hasConcept C86803240 @default.
• W2807009310 hasConceptScore W2807009310C121608353 @default.
• W2807009310 hasConceptScore W2807009310C126322002 @default.
• W2807009310 hasConceptScore W2807009310C141071460 @default.
• W2807009310 hasConceptScore W2807009310C143998085 @default.
• W2807009310 hasConceptScore W2807009310C151730666 @default.
• W2807009310 hasConceptScore W2807009310C197934379 @default.
• W2807009310 hasConceptScore W2807009310C2777658100 @default.
• W2807009310 hasConceptScore W2807009310C2777701055 @default.
• W2807009310 hasConceptScore W2807009310C2779343474 @default.
• W2807009310 hasConceptScore W2807009310C2780030458 @default.
• W2807009310 hasConceptScore W2807009310C2780140570 @default.
• W2807009310 hasConceptScore W2807009310C2781433595 @default.
• W2807009310 hasConceptScore W2807009310C502942594 @default.
• W2807009310 hasConceptScore W2807009310C71924100 @default.
• W2807009310 hasConceptScore W2807009310C86803240 @default.
• W2807009310 hasIssue "1" @default.
• W2807009310 hasLocation W28070093101 @default.
• W2807009310 hasLocation W28070093102 @default.
• W2807009310 hasLocation W28070093103 @default.
• W2807009310 hasLocation W28070093104 @default.
• W2807009310 hasLocation W28070093105 @default.
• W2807009310 hasOpenAccess W2807009310 @default.
• W2807009310 hasPrimaryLocation W28070093101 @default.
• W2807009310 hasRelatedWork W1963731933 @default.
• W2807009310 hasRelatedWork W2888298425 @default.
• W2807009310 hasRelatedWork W2947988614 @default.
• W2807009310 hasRelatedWork W2955428297 @default.
• W2807009310 hasRelatedWork W2963333658 @default.
• W2807009310 hasRelatedWork W2969687411 @default.
• W2807009310 hasRelatedWork W3029766637 @default.
• W2807009310 hasRelatedWork W3215044659 @default.
• W2807009310 hasRelatedWork W4206770832 @default.
• W2807009310 hasRelatedWork W4361939003 @default.
• W2807009310 hasVolume "18" @default.
• W2807009310 isParatext "false" @default.
• W2807009310 isRetracted "false" @default.
• W2807009310 magId "2807009310" @default.
• W2807009310 workType "article" @default.